Небулайзерная терапия Metodichka_Avdeev

43.Global strategy for asthma management and prevention NHLBI/WHO Workshop Report: NIH Publication No 023659. The 2006 report is available on www.ginasthma.com

44.Godfrey S, Avital A, Rosier A, et al. Nebulized budesonide in severe infantile asthma. Lancet 1987; ii: 851-852.

45.Grоnberg S, Magnusson P, Bladh N. Chemical compartibility of budesonide inhalation suspension (Pulmicort Respules™) with other nebulization products. Am J Respir Crit Care Med 2001; 163: A558.

46.Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G. The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur Respir J 2007; 30: 399-400.

47.Gurkan F, Bosnak M. Use of nebulized budesonide in two critical patients with hydrocarbon intoxication. Am J Ther 2005; 12: 366-7.

48.Harriman A-M, Purcell N, Fleming S, et al. Can we mixt nebulizer solutions? Stability of drug admixtures in solutions for nebulizations. Pharm Pract 1996; 6: 347-348.

49.Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355: 542545.

50.Higgenbottam TW, Clark RA, Luksza AR, et al. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur J Clin Res 1994; 5: 1-10.

51.Higgenbottam TW, Britton J, Lawrence D, et al. On behalf of the Pulmicort Respules versus oral steroids: A prospective clinical trial in acute asthma. Comparison of nebulised budesonide and prednisolone in severe asthma exacerbation in adults. BioDrugs 2000; 14: 247254.

52.Hill J.M. Nebulised corticosteroids in the treatment of patients with asthma Thorax 1999; 54: 661663.

53.Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 2006; 27: 172-187.

54.Huiart L, Ernst P, Ranouil X, Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006; 13: 134-8.

55.Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000; 60: 11411178.

56.Jackson WF. Nebulised Pulmocort therapy. A scientific and practical review. Clinical Vision Ltd, Oxford 1998: pp. 83.

57.Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999; 83: 231239.

58.King TE. Overview of bronchiolitis. Clin Chest Med 1993; 14: 607-610.

59.Knoch M, Sommer E. Jet nebulizer design and function. Eur Respir Rev 2000; 10: 183186.

60.Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliver 2005; 2: 377–390.

61.Kumar SD, Emery MJ, Atkins ND, et al. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998; 158: 153-156.

62.Kumar SD, Brieva JL, Danta I, et al. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med 2000; 161: 918-921.

63.Lin RY, Newman TG, Sauter D. et al. Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting. Chest 1994; 106: 452-457.

64.Maltais F, Ostinelli J, Bourbeau J, Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698-703.

65.Marcus P, Oppenheimer EA, Patel PA, et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol 2006; 96: 736-43.

66.Matsumoto H, Ishihara K, Hasegawa T, et al. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: A 4-year longitudinal study. Chest 2001; 120: 1468-1473.

67.McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;

111:732–43.

68.McFadden E.R. Jr. Inhaled corticosteroids and acute asthma. Therapeutic breakthrough or nonspecific effect? Am J Respir Crit Care Med 1998; 157: 677678.

69.McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004; 38: 967-72.

70.Mendes ES, Pereira A, Danta I, et al. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 2003; 21: 989-993.

71.Messer J, Reitman D, Sacks H, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 2124.

72.Miller-Larsson A, Jansson P, Runstrom A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162: 14551461.

73.Mitchell CA, Alpers JH, Morton SM, et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma. Eur Respir J 1995; 8(Suppl.19): 490s.

74.Morice AH, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide wiyth oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996; 60: 675-678.

75.Muers MF. Overview of nebulizer treatment. Thorax 1997; 52 (Suppl.2): S25-S30.

76.Murphy KR, Fitzpatrick S, Cruz-Rivera M, et al. Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma. Pediatrics 2003; 112(3 Pt 1): e212-9.

77.National Institutes of Health. National Heart, Lung, and Blood Institute. Highlights of the Expert panel Report 2: Cuidelines for the diagnosis and management of asthma. NIH publication No. 974051A, may 1997.

78.Nava S, Fracchia C, Callegari G, et al. Weakness of respiratory and sceletal muscles after a short course of steroids in patients with acute lung rejection. Eur Respir J 2002; 20: 497499.

79.Nehme O, Rachoin J-S, Azar M, et al. Glycemic control during inhospital corticosteroid treatment for exaxerbations of obstructive airway disease. Chest Meeting Abstracts 2006; 130: 184S-d-185S-d.

80.Newman SP, Pitcairn GR, Pickford, et al. The MicroAir electronic-mesh nebuliser deposits aerosol in the lungs more efficiently than a conventional jet nebuliser. Drug Delivery to the Lungs XV, The Aerosol Society, London, 2004: 228–231.

81.Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;

340:1941-7.

82.Nikander K. Drug delivery systems. J Aerosol Med 1994; 7(Suppl 1): S19-24.

83.Nikander K. Adaptive aerosol delivery: the principles. Eur Respir Rev 1997; 7: 385-387.

84.Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999 Summer; 12: 47-53

85.O’Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52(Suppl 2): S31-S44.

86.O’Donohue A, and the National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Chest 1996; 109: S14-20.

87.Otulana BA, Varma N, Bullock A, Higgenbottam TW. High dose nebulized steroid in the treatment of steroid-de- pendent asthma. Respir Med 1992; 86: 105108.

88.Packe GE, Douglas JG, McDonald AF, et al. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992; 47: 414-417.

89.Pansegrouw DF. Acute resistant asthma caused by excessive ß-2-adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone. S Afr Med J 1992; 82: 179-182.

90.Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med 1996; 90: 69-77.

91.Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (Suppl.39): 1-34.

92.Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998; 157: 698703.

93.Rodrigo G, Rodrigo C. Corticosteroids in the emergency department therapy of acute adult asthma: An evidencebased evaluation. Chest 1999; 116: 285-295.

94.Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 2003; 123: 1908-1915.

95.Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 2005; 171: 1231-1236.

96.Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. Chest 2006; 130; 1301-1311.

97.Rowe BH, Bota GW, Fabris L, et al. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA 1999; 281: 21192126.

98.Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analy- sis. Am J Emerg Med 1992; 10: 301-310.

99.Rowe BH, Vethanayagam D. The role of inhaled corticosteroids in the management of acute asthma. Eur Respir J 2007; 30: 1035-1037.

100.Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticosteroids in severe exacerbations of COPD. Chest 2001; 119: 726-730.

101.Shale D. Nebulised budesonide therapy in ICU. Care Crit Ill 1996; 12: 15-17.

102.Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998; 102: 789-796.

103.Shee CD. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med 1990; 84: 229-233.

104.Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998; 11: 113-125.

105.Swarbrick J, Boylan JC. Ultrasonic nebulisers. In: Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker; 1997: 339-351.

106.Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999; 104: S175-183.

107.Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109: 730-42.

108.Szefler SJ, Baker J, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120: 1043-1050.

109.Takao M, Higenbottam TW, Audley T, et al. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients. Transplant Proc 1995; 27: 1284-1285.

110.Tashkin DP. Dosing strategies for aerosol delivery to the airways. Respir Care 1991; 36: 977-88.

111.Terajima M, Yamaya M, Sekizawa K, et al. Rhinovirus infection of primary cultures of human tracheal epithelium: role of ICAM-1 and IL-1beta. Am J Physiol 1997; 273: L749–L759.

112.Toogood JH, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 688-700.

113.Vecellio L. The mesh nebulizer: a recent technical innovation for aerosol delivery. Breathe 2006; 2: 253-260

114.Wales D, Makker H, Kane J, et al. Systemic bioavailability and potency of high-dose inhaled corticosteroids. Chest 1999; 115: 1278-1284.

115.Wang J, Zhang L, Walther SM. Inhaled budesonide in experimental chlorine gas lung injury: influence of time interval between injury and treatment. Intensive Care Med 2002; 28: 352-357.

116.Wanner A, Horvath G, Brieva JL, et al. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thorac Soc 2004; 1: 235-238.

117.Wedzicha JA. Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55(Suppl 1): S23-S27.

118.Wilson AM, McFarlane LC, Lipworth BJ. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest 1998; 114: 1022-1029.

119.Wood-Baker R et al., Systemic corticosteroids in chronic obstructive pulmonary disease: An overview of Cochrane systematic reviews. Respir Med 2007; 101: 371-7.

120.Yoshiyama Y, Yazaki T, Arai M, et al. The nebulization of budesonide suspensions by a newly designed mesh nebulizer. In: Dalby RN, Byron PR, Peart J and Farr SF, eds. Respiratory drug delivery VIII. Raleigh: Davis Horwood; 2002: 487–489.